These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 24480077

  • 1. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M, Akhondzadeh S.
    Psychiatry Res; 2014 Mar 30; 215(3):540-6. PubMed ID: 24480077
    [Abstract] [Full Text] [Related]

  • 2. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.
    CNS Drugs; 2013 Jan 30; 27(1):57-65. PubMed ID: 23233269
    [Abstract] [Full Text] [Related]

  • 3. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S.
    J Clin Psychopharmacol; 2013 Jun 30; 33(3):336-42. PubMed ID: 23609382
    [Abstract] [Full Text] [Related]

  • 4. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A, Gholamian F, Tabatabei-Motlagh M, Afarideh M, Rezaei F, Ghazizadeh-Hashemi M, Akhondzadeh S.
    Hum Psychopharmacol; 2018 Jul 30; 33(4):e2662. PubMed ID: 29901250
    [Abstract] [Full Text] [Related]

  • 5. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial.
    Ghanizadeh A, Dehbozorgi S, OmraniSigaroodi M, Rezaei Z.
    Recent Pat Inflamm Allergy Drug Discov; 2014 Jul 30; 8(3):211-5. PubMed ID: 25353174
    [Abstract] [Full Text] [Related]

  • 6. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S.
    J Psychiatr Res; 2013 Apr 30; 47(4):472-8. PubMed ID: 23375406
    [Abstract] [Full Text] [Related]

  • 7. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S.
    Eur Neuropsychopharmacol; 2014 Jun 30; 24(6):846-55. PubMed ID: 24636461
    [Abstract] [Full Text] [Related]

  • 8. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
    Nikbakhat MR, Arabzadeh S, Zeinoddini A, Khalili Z, Rezaei F, Mohammadinejad P, Ghaleiha A, Akhondzadeh S.
    Pharmacopsychiatry; 2016 Jul 30; 49(4):162-9. PubMed ID: 26902281
    [Abstract] [Full Text] [Related]

  • 9. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.
    Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Rezaei F, Salehi B, Ashrafi M, Yekehtaz H, Tabrizi M, Akhondzadeh S.
    Psychopharmacology (Berl); 2013 Aug 30; 228(4):595-602. PubMed ID: 23515583
    [Abstract] [Full Text] [Related]

  • 10. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.
    Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S.
    Clin Neuropharmacol; 2013 Aug 30; 36(6):185-92. PubMed ID: 24201233
    [Abstract] [Full Text] [Related]

  • 11. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
    Moazen-Zadeh E, Bayanati S, Ziafat K, Rezaei F, Mesgarpour B, Akhondzadeh S.
    J Psychopharmacol; 2020 May 30; 34(5):506-513. PubMed ID: 32122230
    [Abstract] [Full Text] [Related]

  • 12. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
    Khodaie-Ardakani MR, Khosravi M, Zarinfard R, Nejati S, Mohsenian A, Tabrizi M, Akhondzadeh S.
    Acta Med Iran; 2015 May 30; 53(6):337-45. PubMed ID: 26069170
    [Abstract] [Full Text] [Related]

  • 13. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A, Khoaie-Ardakani MR, Shahmoradi Z, Alavi AR, Afarideh M, Shalbafan MR, Ghazizadeh-Hashemi M, Akhondzadeh S.
    Psychiatry Res; 2018 Apr 30; 262():94-101. PubMed ID: 29427913
    [Abstract] [Full Text] [Related]

  • 14. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.
    Arch Gen Psychiatry; 2005 Nov 30; 62(11):1196-204. PubMed ID: 16275807
    [Abstract] [Full Text] [Related]

  • 15. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels.
    Zhang L, Zheng H, Wu R, Zhu F, Kosten TR, Zhang XY, Zhao J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul 13; 85():69-76. PubMed ID: 29678772
    [Abstract] [Full Text] [Related]

  • 16. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial.
    Weiser M, Levi L, Burshtein S, Chiriță R, Cirjaliu D, Gonen I, Yolken R, Davidson M, Zamora D, Davis JM.
    Schizophr Res; 2019 Apr 13; 206():325-332. PubMed ID: 30455075
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 13; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 18. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
    Farokhnia M, Sabzabadi M, Pourmahmoud H, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Akhondzadeh S.
    Psychopharmacology (Berl); 2014 Feb 13; 231(3):533-42. PubMed ID: 24013610
    [Abstract] [Full Text] [Related]

  • 19. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S, Yang J, Ruan Y, Zeng Y, Xu X, Zhao J.
    Schizophr Res; 2014 Mar 13; 153(1-3):169-76. PubMed ID: 24503176
    [Abstract] [Full Text] [Related]

  • 20. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe AE, Fernandez de Corres B, Ibáñez A, Huerta R, Abordaje Síntomas Negativos Esquizofrenia Group.
    J Clin Psychiatry; 2014 Jun 13; 75(6):608-15. PubMed ID: 25004184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.